{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T02:28:17Z","timestamp":1789439297284,"version":"build-2803163510"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2020,10,25]],"date-time":"2020-10-25T00:00:00Z","timestamp":1603584000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Interlaken Leadership Award"},{"name":"CSL Behring kindly"},{"name":"IVIg"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>We explored efficacy and safety of IVIg as first-line treatment in patients with an idiopathic inflammatory myopathy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this investigator-initiated phase 2 open-label study, we included 20 adults with a newly diagnosed, biopsy-proven idiopathic inflammatory myopathy, and a disease duration of less than 9\u2009months. Patients with IBM and prior use of immunosuppressants were excluded. The standard treatment regimen consisted of IVIg (Privigen) monotherapy for 9\u2009weeks: a loading dose (2\u2009g\/kg body weight) and two subsequent maintenance doses (1\u2009g\/kg body weight) with a 3-week interval. The primary outcome was the number of patients with at least moderate improvement on the 2016 ACR\/EULAR Total Improvement Score. Secondary outcomes included time to improvement, the number of patients requiring rescue medication and serious adverse events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We included patients with DM (n\u2009=\u20099), immune-mediated necrotizing myopathy (n\u2009=\u20096), non-specific myositis\/overlap myositis (n\u2009=\u20094) and anti-synthetase syndrome (n\u2009=\u20091). One patient was excluded from analyses because of minimal weakness resulting in a ceiling effect. Eight patients (8\/19\u2009=\u200942.0%; Clopper\u2013Pearson 95% CI: 19.6, 64.6) had at least moderate improvement by 9\u2009weeks. Of these, six reached improvement by 3\u2009weeks. Seven patients required rescue medication due to insufficient efficacy and prematurely ended the study. Three serious adverse events occurred, of which one was pulmonary embolism.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>First-line IVIg monotherapy led to at least moderate improvement in nearly half of patients with a fast clinical response in the majority of responders.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration<\/jats:title>\n                  <jats:p>Netherlands Trial Register identifier, NTR6160.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaa459","type":"journal-article","created":{"date-parts":[[2020,7,5]],"date-time":"2020-07-05T19:06:53Z","timestamp":1593976013000},"page":"1784-1792","source":"Crossref","is-referenced-by-count":40,"title":["Intravenous immunoglobulins as first-line treatment in idiopathic inflammatory myopathies: a pilot study"],"prefix":"10.1093","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7565-1954","authenticated-orcid":false,"given":"Johan","family":"Lim","sequence":"first","affiliation":[{"name":"Department of Neurology, Amsterdam UMC, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Eftimov","sequence":"additional","affiliation":[{"name":"Department of Neurology, Amsterdam UMC, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camiel","family":"Verhamme","sequence":"additional","affiliation":[{"name":"Department of Neurology, Amsterdam UMC, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Brusse","sequence":"additional","affiliation":[{"name":"Department of Neurology, Erasmus UMC, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica E","family":"Hoogendijk","sequence":"additional","affiliation":[{"name":"Department of Neurology, Brain Centre Rudolf Magnus, UMC Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiaan G J","family":"Saris","sequence":"additional","affiliation":[{"name":"Department of Neurology, Radboud UMC, Donders Institute for Brain Cognition and Behaviour, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost","family":"Raaphorst","sequence":"additional","affiliation":[{"name":"Department of Neurology, Amsterdam UMC, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob J","family":"De Haan","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo N","family":"van Schaik","sequence":"additional","affiliation":[{"name":"Department of Neurology, Amsterdam UMC, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands"},{"name":"Spaarne Gasthuis, Haarlem, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Aronica","sequence":"additional","affiliation":[{"name":"Department of (Neuro)Pathology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"de Visser","sequence":"additional","affiliation":[{"name":"Department of Neurology, Amsterdam UMC, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneke J","family":"van der Kooi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Amsterdam UMC, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,10,25]]},"reference":[{"key":"2021040620350030000_keaa459-B1","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1007\/s00415-014-7313-z","article-title":"Long-term follow-up of 62 patients with myositis","volume":"261","author":"Van de Vlekkert","year":"2014","journal-title":"J Neurol"},{"key":"2021040620350030000_keaa459-B2","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s11926-012-0249-3","article-title":"Morbidity and mortality in adult polymyositis and dermatomyositis","volume":"14","author":"Marie","year":"2012","journal-title":"Curr Rheumatol Rep"},{"key":"2021040620350030000_keaa459-B3","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.nmd.2010.03.011","article-title":"Oral dexamethasone pulse therapy versus daily prednisolone in sub-acute onset myositis, a randomised clinical trial","volume":"20","author":"Van de Vlekkert","year":"2010","journal-title":"Neuromuscul Disord"},{"key":"2021040620350030000_keaa459-B4","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1001\/jama.291.19.2367","article-title":"Intravenous immunoglobulin in autoimmune neuromuscular diseases","volume":"291","author":"Dalakas","year":"2004","journal-title":"JAMA"},{"key":"2021040620350030000_keaa459-B5","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"N Engl J Med"},{"key":"2021040620350030000_keaa459-B6","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3109\/s10165-011-0534-4","article-title":"Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomised double-blind placebo-controlled trial","volume":"22","author":"Miyasaka","year":"2012","journal-title":"Mod Rheumatol"},{"key":"2021040620350030000_keaa459-B7","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2169\/internalmedicine.35.663","article-title":"Intravenous immunoglobulin therapy for refractory myositis","volume":"35","author":"Moriguchi","year":"1996","journal-title":"Intern Med"},{"key":"2021040620350030000_keaa459-B8","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/s10165-007-0013-0","article-title":"Efficacy of high-dose intravenous immunoglobulin therapy in Japanese patients with steroid-resistant polymyositis and dermatomyositis","volume":"18","author":"Saito","year":"2008","journal-title":"Mod Rheumatol"},{"key":"2021040620350030000_keaa459-B9","first-page":"1092","article-title":"Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients","volume":"21","author":"Cherin","year":"1994","journal-title":"J Rheumatol"},{"key":"2021040620350030000_keaa459-B10","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1056\/NEJMc1506163","article-title":"Intravenous immune globulin for statin-triggered autoimmune myopathy","volume":"373","author":"Mammen","year":"2015","journal-title":"N Engl J Med"},{"key":"2021040620350030000_keaa459-B11","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","article-title":"119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands","volume":"14","author":"Hoogendijk","year":"2004","journal-title":"Neuromuscul Disord"},{"key":"2021040620350030000_keaa459-B12","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/rheumatology\/40.11.1262","article-title":"Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies","volume":"40","author":"Miller","year":"2001","journal-title":"Rheumatology"},{"key":"2021040620350030000_keaa459-B13","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/rheumatology\/keg427","article-title":"International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease","volume":"43","author":"Isenberg","year":"2004","journal-title":"Rheumatology"},{"key":"2021040620350030000_keaa459-B14","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1002\/art.40320","article-title":"2017 European League against Rheumatism\/American College of Rheumatology Classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"69","author":"Lundberg","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2021040620350030000_keaa459-B15","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1001\/jamaneurol.2018.2598","article-title":"Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies","volume":"75","author":"Mariampillai","year":"2018","journal-title":"JAMA Neurol"},{"key":"2021040620350030000_keaa459-B16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2016.02.017","article-title":"Testing for myositis specific autoantibodies: comparison between line blot and immunoprecipitation assays in 57 myositis sera","volume":"433","author":"Cavazzana","year":"2016","journal-title":"J Immunol Methods"},{"key":"2021040620350030000_keaa459-B17","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s12026-016-8867-x","article-title":"Anti-HMGCR antibodies demonstrate high diagnostic value in the diagnosis of immune-mediated necrotizing myopathy following statin exposure","volume":"65","author":"Shovman","year":"2017","journal-title":"Immunol Res"},{"key":"2021040620350030000_keaa459-B18","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1474-4422(07)70329-0","article-title":"Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial","volume":"7","author":"Hughes","year":"2008","journal-title":"Lancet Neurol"},{"key":"2021040620350030000_keaa459-B19","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/art.40064","article-title":"2016 American College of Rheumatology\/European League against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: an International Myositis Assessment and Clinical Studies Group\/Paediatric Rheumatology International Trials Organisation Collaborative Initiative","volume":"69","author":"Aggarwal","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2021040620350030000_keaa459-B20","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1093\/brain\/awr318","article-title":"Modifying the Medical Research Council grading system through Rasch analyses","volume":"135","author":"Vanhoutte","year":"2012","journal-title":"Brain"},{"key":"2021040620350030000_keaa459-B21","doi-asserted-by":"crossref","first-page":"e0194531","DOI":"10.1371\/journal.pone.0194531","article-title":"Manual muscle testing and hand-held dynamometry in people with inflammatory myopathy: an intra- and interrater reliability and validity study","volume":"13","author":"Baschung Pfister","year":"2018","journal-title":"PLoS One"},{"key":"2021040620350030000_keaa459-B22","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1159\/000110176","article-title":"Amyotrophic lateral sclerosis severity scale","volume":"8","author":"Hillel","year":"1989","journal-title":"Neuroepidemiology"},{"key":"2021040620350030000_keaa459-B23","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1136\/jnnp.54.12.1044","article-title":"The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results","volume":"54","author":"Farrell","year":"1991","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2021040620350030000_keaa459-B24","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1007\/s11136-012-0322-4","article-title":"Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study","volume":"22","author":"Janssen","year":"2013","journal-title":"Qual Life Res"},{"key":"2021040620350030000_keaa459-B25","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"key":"2021040620350030000_keaa459-B26"},{"key":"2021040620350030000_keaa459-B27","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/00001648-199001000-00010","article-title":"No adjustments are needed for multiple comparisons","volume":"1","author":"Rothman","year":"1990","journal-title":"Epidemiology"},{"key":"2021040620350030000_keaa459-B28","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1002\/acr.21728","article-title":"Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation-associated gene 5 antibody","volume":"64","author":"Cao","year":"2012","journal-title":"Arthritis Care Res"},{"key":"2021040620350030000_keaa459-B29","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/acr.21992","article-title":"Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum","volume":"65","author":"Hall","year":"2013","journal-title":"Arthritis Care Res"},{"key":"2021040620350030000_keaa459-B30","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/archdermatol.2011.52","article-title":"Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study","volume":"147","author":"Hamaguchi","year":"2011","journal-title":"Arch Dermatol"},{"key":"2021040620350030000_keaa459-B31","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/01.md.0000173991.74008.b0","article-title":"Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients","volume":"84","author":"Troyanov","year":"2005","journal-title":"Medicine"},{"key":"2021040620350030000_keaa459-B32","doi-asserted-by":"crossref","first-page":"e513","DOI":"10.1212\/NXI.0000000000000513","article-title":"Seronegative patients form a distinctive subgroup of immune-mediated necrotizing myopathy","volume":"6","author":"Lim","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2021040620350030000_keaa459-B33","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.3899\/jrheum.161480","article-title":"Clinical profiles and prognosis of patients with distinct antisynthetase autoantibodies","volume":"44","author":"Shi","year":"2017","journal-title":"J Rheumatol"},{"key":"2021040620350030000_keaa459-B34","doi-asserted-by":"crossref","first-page":"e60442","DOI":"10.1371\/journal.pone.0060442","article-title":"Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome","volume":"8","author":"Hamaguchi","year":"2013","journal-title":"PLoS One"},{"key":"2021040620350030000_keaa459-B35","doi-asserted-by":"crossref","first-page":"102426","DOI":"10.1016\/j.autrev.2019.102426","article-title":"Subcutaneous immunoglobulin in inflammatory myopathies: efficacy in different organ systems","volume":"19","author":"Danieli","year":"2020","journal-title":"Autoimmun Rev"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/4\/1784\/36913619\/keaa459.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/4\/1784\/36913619\/keaa459.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T23:36:41Z","timestamp":1617752201000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/4\/1784\/5939817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,25]]},"references-count":35,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,10,25]]},"published-print":{"date-parts":[[2021,4,6]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa459","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,4,1]]},"published":{"date-parts":[[2020,10,25]]}}}